Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Cytomorphologic features of malignant solitary fibrous tumor with mediastinal involvement sampled by endoscopic and endobronchial ultrasound-guided fine-needle aspiration: A comparison of two cases.

Hupp M, Najmuddin M, Dincer HE, Mallery JS, Amin K, Stewart J 3rd.

Diagn Cytopathol. 2019 Aug;47(8):821-827. doi: 10.1002/dc.24192. Epub 2019 Apr 24.

PMID:
31016889
2.

Sarcomatoid carcinoma in cytology: Report of a rare entity presenting in pleural and pericardial fluid preparations.

Basu A, Moreira AL, Simms A, Brandler TC.

Diagn Cytopathol. 2019 Aug;47(8):813-816. doi: 10.1002/dc.24183. Epub 2019 Mar 25.

PMID:
30908904
3.

STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma.

Miloudi H, Leroy K, Jardin F, Sola B.

Cell Signal. 2018 Jun;46:76-82. doi: 10.1016/j.cellsig.2018.02.016. Epub 2018 Mar 1.

PMID:
29501729
4.

The clinicopathological significance of NAB2-STAT6 gene fusions in 52 cases of intrathoracic solitary fibrous tumors.

Huang SC, Li CF, Kao YC, Chuang IC, Tai HC, Tsai JW, Yu SC, Huang HY, Lan J, Yen SL, Lin PC, Chen TC.

Cancer Med. 2016 Feb;5(2):159-68. doi: 10.1002/cam4.572. Epub 2015 Dec 21.

5.

Knock-down of BCL6 / STAT6 sensitizes primary B cell lymphoma cells for treatment with current therapeutic agents.

Häberle MT, Kelsch E, Dorsch K, Möller P, Ritz O.

Oncoscience. 2014 Apr 30;1(4):283-6. eCollection 2014.

6.

Targeting STAT6 in PMBL.

Leroy K, Pujals A, Pelletier L.

Oncotarget. 2014 Sep 15;5(17):7216. No abstract available.

7.

Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.

Hao Y, Chapuy B, Monti S, Sun HH, Rodig SJ, Shipp MA.

Clin Cancer Res. 2014 May 15;20(10):2674-83. doi: 10.1158/1078-0432.CCR-13-3007. Epub 2014 Mar 7.

8.

STAT6 is amplified in a subset of dedifferentiated liposarcoma.

Doyle LA, Tao D, Mariño-Enríquez A.

Mod Pathol. 2014 Sep;27(9):1231-7. doi: 10.1038/modpathol.2013.247. Epub 2014 Jan 24.

9.

STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL).

Ritz O, Rommel K, Dorsch K, Kelsch E, Melzner J, Buck M, Leroy K, Papadopoulou V, Wagner S, Marienfeld R, Brüderlein S, Lennerz JK, Möller P.

Oncotarget. 2013 Jul;4(7):1093-102.

10.

Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets.

Raia V, Schilling M, Böhm M, Hahn B, Kowarsch A, Raue A, Sticht C, Bohl S, Saile M, Möller P, Gretz N, Timmer J, Theis F, Lehmann WD, Lichter P, Klingmüller U.

Cancer Res. 2011 Feb 1;71(3):693-704. doi: 10.1158/0008-5472.CAN-10-2987. Epub 2010 Dec 2.

11.

Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.

Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais JP, Dubois G, Gaulard P, Möller P, Leroy K.

Blood. 2009 Aug 6;114(6):1236-42. doi: 10.1182/blood-2009-03-209759. Epub 2009 May 7.

12.

STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-cell lymphoma.

Ritz O, Guiter C, Dorsch K, Dusanter-Fourt I, Wegener S, Jouault H, Gaulard P, Castellano F, Möller P, Leroy K.

Leukemia. 2008 Nov;22(11):2106-10. doi: 10.1038/leu.2008.85. Epub 2008 Apr 10. No abstract available.

PMID:
18401415
13.

Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma.

Guiter C, Dusanter-Fourt I, Copie-Bergman C, Boulland ML, Le Gouvello S, Gaulard P, Leroy K, Castellano F.

Blood. 2004 Jul 15;104(2):543-9. Epub 2004 Mar 25.

PMID:
15044251

Supplemental Content

Loading ...
Support Center